Marketwatch Buy Aurobindo Pharma, target price Rs 450: Motilal Oswal Admin April 3, 2020 The brokerage has reduced its earnings estimate for FY21/FY22 by 19 per cent/18 per cent to Rs 51/Rs 53 to factor in termination of Sandoz acquisition plan. – Stocks-Markets-Economic Times Share on Facebook Tweet it Pin it Share it Email
